{'fraction_non_alphanumeric': 0.032454361054766734, 'fraction_numerical': 0.038539553752535496, 'mean_word_length': 6.057142857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EFFECT OF CHRONIC TREATMENT WITH ME3221 ON BLOOD PRESSURE AND MORTALITY IN AGED STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS

1. The protective effect of ME3221, a surmountable AT1 antagonist, on the hypertension and its concomitant complications in aged (32 week old) stroke‐prone spontaneously hypertensive rats (SHRSP) was studied following long‐term (32 weeks) oral administration, and compared with those of losartan (metabolite EXP3174 is an insurmountable AT1 antagonist) and enalapril.